Figure 1. a. Median overall survival was 67 months. b. Patients with H3K27M mutations had a shorter overall survival c. Patients with citrate levels >1.2 had a shorter overall survival but this was not significant. d. Patients with high grade gliomas had a shorter survival as expected.